Page 5 - Jonae Barnes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Atea Pharmaceuticals Inc (AVIR) Q2 2021 Earnings Call Transcript

AVIR earnings call for the period ending June 30, 2021.

United statesJean pierre sommadossiJonathan miller evercoreJohn vavrickaJanet hammondJonathan millerTim lugoAndrea corcoranDeric josephWilliam blairJonae barnesExchange commissionAtea pharmaceuticalsCorporate communicationsLachlan hanbury brown william blair company analystAtea pharmaceuticals inc

Atea Pharmaceuticals Appoints Claudio Avila, MB, BS, Ph D , as Senior Vice President of Medical Affairs

Atea Pharmaceuticals Appoints Claudio Avila, MB, BS, Ph D , as Senior Vice President of Medical Affairs
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNew south walesUnited kingdomJean pierre sommadossiClaudio avilaJonae barnesSydney universityFounder of atea pharmaceuticalsAtea pharmaceuticalsGilead sciencesMelbourne universityAtea pharmaceuticals incGlobal programSenior vice presidentExecutive directorMedical affairs

Atea Pharmaceuticals Appoints Jerome Adams, M D , M P H , to Board of Directors

Atea Pharmaceuticals Appoints Jerome Adams, M D , M P H , to Board of Directors
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesIndiana universityJean pierre sommadossiJerome adamsJonae barnesUniversity of californiaFounder of atea pharmaceuticalsDepartment of anesthesiology at indiana universityClinical research assistant at eli lillyUniversity of marylandIndiana university school of medicineIndiana society of anesthesiologistsAmerican medical associationAtea pharmaceuticalsIndiana state medical associationAtea pharmaceuticals inc

Atea Pharmaceuticals Appoints Jerome Adams, M D , M P H , to Board of DirectorsFormer U S Surgeon General Brings Wealth of Clinical and Public Health Experience

Atea Pharmaceuticals Appoints Jerome Adams, M D , M P H , to Board of DirectorsFormer U S Surgeon General Brings Wealth of Clinical and Public Health Experience
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.

Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19

Home / Top News / Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19 Atea Pharmaceuticals Announces First Patient Dosed in Global Phase 3 MORNINGSKY Trial of AT-527 for Treatment of COVID-19 Phase 3 trial to evaluate efficacy and safety of AT-527, an oral antiviral for treatment of patients with mild to moderate COVID-19 in outpatient setting BOSTON, April 29, 2021 (GLOBE NEWSWIRE) Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in the Phase 3 MORNINGSKY trial, a global multicenter trial evaluating AT-527 in mild or moderate COVID-19 patients in an outpatient setting. The trial, which is anticipated to enroll approximately 1,400 non-hospitalized adults and adolescents with mild to moderate COVID-19, is currently enrolling patients at clinical trial sites outside the United States. MORNINGSKY is expected

United statesJean pierre sommadossiJonae barnesAtea pharmaceuticalsCorporate communicationsAtea pharmaceuticals incClinical development programChief executive officerPrivate securities litigation reform actAnnual reportInvestor relationsஒன்றுபட்டது மாநிலங்களில்பெருநிறுவன தகவல்தொடர்புகள்மருத்துவ வளர்ச்சி ப்ரோக்ர்யாம்தலைமை நிர்வாகி அதிகாரிப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம்